Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"

Description

This is an international prospective, multicentre, unblinded, randomised-controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients.

Conditions

Heart Failure, Cardiovascular Diseases

Study Overview

Study Details

Study overview

This is an international prospective, multicentre, unblinded, randomised-controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients.

Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY

Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"

Condition
Heart Failure
Intervention / Treatment

-

Contacts and Locations

Cleveland

Cleveland Clinic, Cleveland, Ohio, United States, 44195

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male or female ≥40 years of age
  • * Informed consent
  • * Two or more of the following risk factors for heart failure:
  • 1. Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis of an epicardial coronary artery \[50% left main stem or \>70% left anterior descending, circumflex or right coronary artery\])
  • 2. An established diagnosis of diabetes (type 1 or type 2)
  • 3. Persistent or permanent atrial fibrillation (not paroxysmal atrial fibrillation)
  • 4. Previous ischemic or embolic stroke
  • 5. Peripheral arterial disease (previous surgical or percutaneous revascularisation or a documented stenosis greater than 50% of a major peripheral arterial vessel).
  • 6. Chronic kidney disease (defined as an estimated glomerular filtration rate \<60mL/min/1.73m2 or eGFR 60-90mL/min/1.73m2 and UACR \>300mg/g).
  • 7. Regular loop diuretic use (any dose at any dosing interval) for \>30 days.
  • 8. COPD (evidenced by one of the following: PFTs showing airway obstruction, diagnosis by respiratory physician, CT scan reporting presence of emphysema or treatment with national guideline advocated COPD therapy).
  • * Inability to give informed consent e.g., due to significant cognitive impairment
  • * Previous documented diagnosis of heart failure
  • * Current renal replacement therapy
  • * Anyone who, in the investigators' opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period

Ages Eligible for Study

40 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NHS Greater Glasgow and Clyde,

Mark C Petrie, MbChB, PRINCIPAL_INVESTIGATOR, University of Glasgow

Carolyn SP Lam, PRINCIPAL_INVESTIGATOR, Duke-NUS Graduate Medical School

Study Record Dates

2032-12-21